How Japanese companies face new challenges will determine the future size and shape of their role within the global industry. This Scrip analysis surveys changes over the past decade and analyses Japan pharma's current corporate and regulatory environment.
Key topics covered:
- Evolution of Japan's pharmaceutical industry - Corporate culture shifts - Domestic pressures and foreign market entrants - Generic drugs under-represented in Japan - Challenges for emerging biotech - Japan's 'drug lag' problem - Japanese corporate activity - Japan: source of the next blockbusters?
